Printer Friendly

ALAMAR BIOSCIENCES REPORTS THIRD QUARTER, NINE MONTHS RESULTS

 SACRAMENTO, Calif., Aug. 5 /PRNewswire/ -- Alamar Biosciences Inc. (NASDAQ: ALMR), a research and development company in the in vitro diagnostic field, today announced financial results for the third quarter and nine months ended June 30, 1993.
 For the third quarter, revenues increased 2824 percent to $143,300, compared to $4,900 for the same period last year. Revenues primarily consisted of international and domestic sales of bacterial susceptibility test kits and alamarBlue(TM), and international sales of the semi-automated reading instrument. Revenues were also recorded from Alamar's development agreement with Pfizer Inc. for the development of a yeast susceptibility test. Alamar reported a net loss for the quarter of $844,000, or 28 cents per share, compared to $762,800, or 34 cents per share, for the third quarter in 1992.
 Year to date revenues were $274,100 for the nine months ended June 30, 1993, compared to $11,300 for the same period last year. The company reported a net loss of $2,502,800, or 86 cents per share, for the nine months, compared to $2,332,100, or $1.05 per share, for the comparative period a year ago.
 Mark Santor, chief financial officer, said that while the company is awaiting U.S. Food and Drug Administration clearance on its third test kit, for bacterial identification, sales of its two other test kits and international sales are growing. "Even though we do not have a complete bacterial product line yet, we have been increasingly successful in generating interest in Alamar products. This is evidenced by the jump in sales from last year's third quarter. Once the last test kit is cleared, we will be able to offer a complete line of products that addresses two-thirds of an estimated $530 million market."
 During the quarter, Alamar entered into several distribution agreements with international distributors, making certain of its products available in France, Spain, Mexico, Latin America, parts of Africa and Japan. Alamar test kits are designed to provide quick, easy- to-interpret results in determining the type of antibiotic most effective in treating bacterial infections.
 At June 30, 1993, the company had $948,700 in cash and cash equivalents, working capital of approximately $1.1 million, $1.7 million in shareholders' equity, and $36,500 in long-term debt. As previously announced, Alamar is seeking to raise up to $2 million through a series of private offerings.
 Alamar Biosciences Inc. is a research and development company that develops, manufactures and markets in vitro (outside the body) diagnostic testing products to identify the type of bacteria and antibiotic level effective in treating bacterial infections, as well as alamarBlue(TM), a nontoxic indicator dye for use in diagnostic testing of pharmaceuticals, cosmetics, household cleaners and personal hygiene products.
 Alamar's common stock is traded on the NASDAQ under the symbol ALMR.
 -0- 8/5/93
 /CONTACT: Mark Santor of Alamar Biosciences, 916-567-3475; or Elizabeth Truax of the Financial Relations Board, 415-986-1591/
 (ALMR)


CO: Alamar Biosciences Inc. ST: California IN: MTC SU: ERN

TM -- SF004 -- 9718 08/05/93 09:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 5, 1993
Words:508
Previous Article:RIBI IMMUNOCHEM REPORTS SECOND QUARTER FINANCIAL RESULTS
Next Article:TAB DECLARES REDUCED CASH DIVIDEND AND ANNOUNCES COST REDUCTION PROGRAM
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters